Inhibitory effect of interferon-α-2b on expression of cyclooxygenase-2 and vascular endothelial growth factor in human hepatocellular carcinoma inoculated in nude mice

World Journal of Gastroenterology

Volumn 14, Issue 44, 2008, Pages 6802-6807

  Cao, Bin ^a   Chen, Xiao Ping ^a   Zhu, Peng ^a   Ding, Lei ^a   Guan, Jian ^a   Shi, Zuo Liang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Apoptosis; Cyclooxygenase 2; Hepatocellular carcinoma; Interferon 2b; Vascular endothelial growth factor

Indexed keywords

ALPHA2B INTERFERON; CYCLOOXYGENASE 2; SODIUM CHLORIDE; VASCULOTROPIN; ANTINEOPLASTIC AGENT; MESSENGER RNA; PTGS2 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER TRANSPLANTATION; CELL STRAIN HEPG2; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE COMPARISON; GROWTH INHIBITION; HUMAN; HUMAN CELL; INHIBITION KINETICS; LIVER CELL CARCINOMA; MOUSE; NICK END LABELING; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECT; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON ALFA-2B; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 64049105825     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.6802     Document Type: Article

References (27)

1. Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12: S294-S308 (Pubitemid 27504905)
2. Oshima M, Murai N, Kargman S, Arguello M, Luk P, Kwong E, Taketo MM, Evans JF. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001; 61: 1733-1740 (Pubitemid 34292612)
3. Hussain T, Gupta S, Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 2003; 191: 125-135
4. Peng JP, Su CY, Chang HC, Chai CY, Hung WC. Overexpression of cyclo-oxygenase 2 in squamous cell carcinoma of the hypopharynx. Hum Pathol 2002; 33: 100-104 (Pubitemid 34112958)
5. Sung YK, Hwang SY, Kim JO, Bae HI, Kim JC, Kim MK. The correlation between cyclooxygenase-2 expression and hepatocellular carcinogenesis. Mol Cells 2004; 17: 35-38 (Pubitemid 39137041)
6. Shiota G, Okubo M, Noumi T, Noguchi N, Oyama K, Takano Y, Yashima K, Kishimoto Y, Kawasaki H. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 1999; 46: 407-412
7. Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K, Harada M, Kusaba T, Tanaka M, Kimura R, Nakashima Y, Nakashima O, Kojiro M, Kurohiji T, Sata M. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 1999; 29: 688-696
8. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757-1763
9. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79: 185-188 (Pubitemid 24324908)
10. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364 (Pubitemid 26272076)
11. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-1039
12. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-248
13. El-Assal ON, Yamanoi A, Soda Y, Yamaguchi M, Igarashi M, Yamamoto A, Nabika T, Nagasue N. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 1998; 27: 1554-1562
14. Baron S, Dianzani F. The interferons: a biological system with therapeutic potential in viral infections. Antiviral Res 1994; 24: 97-110 (Pubitemid 24228865)
15. Hertzog PJ, Hwang SY, Kola I. Role of interferons in the regulation of cell proliferation, differentiation, and development. Mol Reprod Dev 1994; 39: 226-232 (Pubitemid 24312166)
16. Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA 1994; 91: 1198-1205
17. Dinney CP, Bielenberg DR, Perrotte P, Reich R, Eve BY, Bucana CD, Fidler IJ. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 1998; 58: 808-814 (Pubitemid 28099496)
18. Singer CA, Baker KJ, McCaffrey A, AuCoin DP, Dechert MA, Gerthoffer WT. p38 MAPK and NF-kappaB mediate COX-2 expression in human airway myocytes. Am J Physiol Lung Cell Mol Physiol 2003; 285: L1087-L1098
19. Manna SK, Mukhopadhyay A, Aggarwal BB. IFN-alpha suppresses activation of nuclear transcription factors NFkappa B and activator protein 1 and potentiates TNF-induced apoptosis. J Immunol 2000; 165: 4927-4934 (Pubitemid 30809417)
20. Slaton JW, Karashima T, Perrotte P, Inoue K, Kim SJ, Izawa J, Kedar D, McConkey DJ, Millikan R, Sweeney P, Yoshikawa C, Shuin T, Dinney CP. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Clin Cancer Res 2001; 7: 2840-2853
21. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-716 (Pubitemid 28257578)
22. Huang SF, Kim SJ, Lee AT, Karashima T, Bucana C, Kedar D, Sweeney P, Mian B, Fan D, Shepherd D, Fidler IJ, Dinney CP, Killion JJ. Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel. Cancer Res 2002; 62: 5720-5726 (Pubitemid 35204727)
23. Wang L, Wu WZ, Sun HC, Wu XF, Qin LX, Liu YK, Liu KD, Tang ZY. Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg 2003; 7: 587-594 (Pubitemid 36875750)
24. Darnell JE Jr. STATs and gene regulation. Science 1997; 277: 1630-1635
25. Alexander WS, Starr R, Fenner JE, Scott CL, Handman E, Sprigg NS, Corbin JE, Cornish AL, Darwiche R, Owczarek CM, Kay TW, Nicola NA, Hertzog PJ, Metcalf D, Hilton DJ. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 1999; 98: 597-608
26. Suzuki A, Hanada T, Mitsuyama K, Yoshida T, Kamizono S, Hoshino T, Kubo M, Yamashita A, Okabe M, Takeda K, Akira S, Matsumoto S, Toyonaga A, Sata M, Yoshimura A. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med 2001; 193: 471-481
27. Giambartolomei S, Artini M, Almerighi C, Moavero SM, Levrero M, Balsano C. Nonsteroidal anti-inflammatory drug metabolism potentiates interferon alfa signaling by increasing STAT1 phosphorylation. Hepatology 1999; 30: 510-516 (Pubitemid 29357518)